Key result
Colchicine repurposing targets residual cardiovascular risk and protects against recurrent events via anti-inflammatory mechanisms.
Why the study?
Inflammatory processes in atherogenesis are increasingly recognized, and targeted anti-inflammatory therapy has shown cardiovascular protection without lipid level changes.
Answers are grounded in this paper and cite their sources.
Over the last decades, our understanding of inflammatory processes involved in atherogenesis advanced considerably, with elements of R. Virchow's concept on atherosclerosis as a chronic inflammation induced by cholesterol appearing highly topical. Indeed, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) taught us that specifically targeted anti-inflammatory therapy can confer protection from recurrent cardiovascular (CV) events without affecting lipid levels.
No takes yet. Share an insight, caveat, or question.
Kraler et al. (2020) conducted a review in Cardiovascular risk. Colchicine was evaluated. The abstract discusses repurposing colchicine for residual cardiovascular risk and notes that anti-inflammatory therapy protects against recurrent events, but reports no quantitative data.
Synapse has enriched 10 related papers. Consider them for comparative context: